Mesoblast Shows Strong Ryoncil™ Results, Eyes Adult Trial Expansion

Australian biotech company Mesoblast Ltd (ASX: MSB, Nasdaq: MESO) has released encouraging new data for its cell therapy Ryoncil™ (remestemcel‑L), used to treat steroid-refractory acute graft-versus-host disease (SR‑aGvHD). The update was presented at the 2026 Tandem Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Centre for Blood and Marrow Transplant Research (CIBMTR) in Utah.

Key Clinical Findings

The real-world data show high survival rates for Ryoncil in both children and adults, including patients who had not responded to other treatments like ruxolitinib. These results support Mesoblast’s plans to launch a pivotal adult trial, potentially expanding the therapy to a much larger patient population.

Ryoncil remains the first FDA-approved mesenchymal stromal cell therapy and the only approved treatment for children under 12 with SR‑aGvHD. The new data also highlight the potential benefits of earlier treatment with Ryoncil, reinforcing its value in transplant care.

Commercial and Strategic Outlook

Since FDA approval, Ryoncil has been gradually rolled out to transplant centers across the U.S., with efforts underway to secure reimbursement and broader adoption. Mesoblast is also engaging with regulators regarding its chronic pain cell therapy candidate, which could expand its pipeline in the future.

Despite the positive clinical news, Mesoblast’s stock has seen mixed reactions, reflecting investor caution as the company transitions from pediatric use into adult clinical trials. Analysts note that upcoming adult trial results and continued real-world adoption will be key drivers for both regulatory approval and commercial success.

Looking Ahead

Mesoblast’s near-term priorities include:

• Conducting the adult SR‑aGvHD pivotal trial.

• Expanding Ryoncil adoption in the U.S. transplant market.

• Monitoring ongoing regulatory discussions and pipeline opportunities, including chronic pain therapy programs.

Overall, Mesoblast continues to make steady clinical and commercial progress, with the potential for broader patient impact as new data and trials support its therapies.